Akcea, Ionis Slide After FDA Document Highlights Volanesorsen
Shares of Ionis Pharmaceuticals (IONS) and its majority-owned spinout Akcea Therapeutics (AKCA) are sliding after the Food and Drug Administration posted its briefing document ahead of Thursday’s meeting to discuss the latter’s volanesorsen. The internal review reflected deep concerns about the safety of the drug. INTERNAL REVIEW: An FDA panel posted its briefing document ahead…